Orion Clinical Revenue and Competitors

Slough, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Orion Clinical's estimated annual revenue is currently $91.9M per year.(i)
  • Orion Clinical's estimated revenue per employee is $201,000

Employee Data

  • Orion Clinical has 457 Employees.(i)
  • Orion Clinical grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$715.5M28855%$1.8MN/A
#2
$7.6M380%N/AN/A
Add Company

Simbec-Orion Group is a full-service, boutique CRO which offers specialist expertise in oncology, rare & orphan diseases, dermatology, respiratory, neurology and infectious diseases and translational medicine. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Simbec-Orion Group supports its clients’ development programmes with our in-house central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy and medical management. Rare and Orphan, Oncology, Pharmacovigilance, Phase I-Phase IV, Clinical Research Organisation, Drug Development, Strategic Development and Planning, Regulatory Planning, Oracle Clinical Systems, Biotechnology and Pharmaceutical, FDA, MHRA, EMA

keywords:N/A

N/A

Total Funding

457

Number of Employees

$91.9M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Orion Clinical News

2022-04-19 - Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China

... additional ongoing or planned large clinical studies for darolutamide across ... Darolutamide is developed jointly by Orion and Bayer.

2022-04-13 - Darolutamide Triplet Therapy Improves Survival In mHSPC

Originally published by our sister publication, Clinical Oncology News. ... Bayer/Orion) to androgen deprivation therapy (ADT) and...

2022-03-30 - Orion to Refocus R&D to Cancer and Pain

We have promising new research projects for pain management, and we expect to proceed to clinical trials within the next 12 months. We have also...

2021-06-04 - Upcoming Panel Discussion, Hosted by Xtalks on Precision Oncology: An Era that Calls for a New Model for Conducting Clinical Trials?

Clinical trials have evolved from drug- to target-oriented trials, and this shift has raised several challenges. TORONTO, Ontario (PRWEB) June 04, 2021 Genomic sequencing techniques and bioinformatics have led us to a better understanding of cancer biology, resulting in a shift from empirical ...

2021-05-12 - Accelerate Early Clinical Development with Adaptive, Multi-Part, First-in-Human Study Design | Upcoming Webinar Hosted by Xtalks

Proactively planning for additional study elements gives greater flexibility, allowing you to make decisions based on emerging data, without requiring additional regulatory approval. TORONTO (PRWEB) May 12, 2021 In early clinical development, making changes to a study design after regulatory a ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$169.7M4686%N/A
#2
$190.9M470-3%N/A
#3
$224.6M58911%N/A
#4
$225.3M591-5%N/A
#5
$107.3M59224%N/A